Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Coagulation factor IX is a protein essential for normal blood clotting and hemostasis. It is produced in the liver and circulates in the bloodstream in an inactive form until activated by injury. Upon activation (to Factor IXa), it interacts with Factor VIIIa to form a complex that activates Factor X—an integral step in the blood coagulation cascade[3][5][6][8]. Pharmaceutical forms of this drug include both plasma-derived and recombinant products; recombinant versions are produced using genetically engineered cell lines (such as CHO cells) to replicate human Factor IX[3]. Coagulation factor IX is primarily indicated for the treatment and prevention of bleeding episodes in patients with hemophilia B (congenital Factor IX deficiency or Christmas disease)[1][2][4]. It does not treat hemophilia A or other clotting disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on coagulation factor ix.